A pioneering treatment has shown extraordinary potential for treating spina bifida in the womb, offering new hope to families affected by this serious birth defect. The results, published in the prestigious Lancet medical journal, represent what scientists are calling a "major step toward a new kind of fetal therapy."
How It Works
Spina bifida is a condition in which a baby's spinal cord is not properly enclosed during gestation, potentially leading to a range of lifelong disabilities including mobility challenges. The new treatment involves applying stem cells harvested from the mother's own placenta to the baby's spine while surgeons simultaneously repair it in the womb.
The approach was developed by researchers at the University of California Davis Department of Surgery, led by Diana Farmer, chair of the department, who said the procedure "paves the way for new treatment options for children with birth defects."
Real Families, Real Results
Six mothers took part in the phase one trial. Among them was Michelle Johnson, whose son Tobi was born in 2022 after receiving the in-utero treatment.
"Our family couldn't feel more blessed," said Johnson. "Tobi's physical and mental abilities are nothing short of a miracle."
The trial showed that the stem cell treatment improved children's mobility and quality of life beyond what conventional fetal surgery alone could achieve.
What's Next
Co-inventor of the treatment Aijun Wang described it as a "major step toward a new kind of fetal therapy," while UK-based spina bifida charity Shine called the results "very exciting."
While further research and larger trials are needed, the implications are profound. The ability to use a mother's own cells to heal her baby before birth represents a fundamental shift in how we approach congenital conditions — treating them before they can cause lasting damage.
Sources: The Lancet, University of California Davis, Positive News, Shine charity
